Advertisement

Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px
Document › Details

Agilent Technologies Inc.. (9/16/12). "Press Release: Agilent Technologies Joins Forces with Molecular Discovery to Address Complex Problems in Drug Research and Development. Combination of Mass-MetaSite Software and High-resolution LC/MS Hardware". Sant

Organisation Organisation Molecular Discovery Ltd.
Products Product Mass-MetaSite software
  Product 2 RapidFire™ 360 Mass Spectrometry system
Index term Index term Agilent–Molecular Discovery: mass spectrometry software, 201209– co-marketing Mass-MetaSite s/w w Agilent LC/MS hardware for metabolite identification
Persons Person Salem, Gustavo (Gus) (IDEX 201605 Group President of IDEX Health & Science before Siscapa + Agilent + Assay Designs)
  Person 2 Cruciani, Gabriele (Molecular Discovery 201209 Managing Director)
     


Combination of Mass-MetaSite Software and High-Resolution LC/MS Hardware Will Reduce Costs and Speed Up Metabolite Identification/Analysis


Agilent Technologies Inc. (NYSE: A) today announced that it has entered into a comarketing agreement with Molecular Discovery Ltd. to provide biopharmaceutical researchers with an advanced metabolite-identification platform. The companies will comarket the combined assets of Agilent's high-resolution liquid chromatography/mass spectrometry (LC/MS) technology and Molecular Discovery's Mass-MetaSite software to enable superior identification and analysis of complex biological mixtures.

"Until now, the challenges of identifying and predicting human drug metabolism have been major obstacles in the development of safe, effective drug candidates," said Gus Salem, vice president and general manager of Agilent's Biological Systems Division. "Together, Agilent Technologies and Molecular Discovery are working to solve this problem in pharmaceutical research. Whereas traditional metabolite identification, synthesis and toxicity testing has been costly and time consuming for researchers, our combined industry-leading technologies will now give them faster, more accurate data, and the confidence they need to ensure the safety of their products much earlier in the preclinical phase of development.

"For example," Salem continued, "the Agilent RapidFire 360 product is used to increase sample throughput for pharmaceutical discovery. With Molecular Discovery's expertise in xenobiotic metabolism and predictive software, the analytical interpretation burden is dramatically reduced. This allows researchers to process the majority of their results automatically and focus their expertise on the more complex cases, streamlining data processing and metabolite identification."

Gabriele Cruciani, managing director at Molecular Discovery, added, "Agilent's leading LC/MS platform is enabling companies to obtain high-quality analytical data with a much higher throughput than before. This means that the experts now need to interpret even more data. Working together with Agilent, we are seamlessly combining these high-throughput hardware capabilities with Molecular Discovery's high-throughput software capabilities, providing a revolutionary advanced metabolite identification platform."

Metabolites are small molecules that are the products of life in the cells of every type of plant or animal. Scientists study snapshots of all the metabolites in a given bio-sample in their search for new therapeutics and to understand the mechanisms of disease and health. Agilent is a world leader in providing sophisticated LC/MS technology for advances in this area.

Prior to the approval of any new drug application, the U. S. Food and Drug Administration requires that all therapeutic compounds be subjected to preclinical metabolic toxicity testing before human clinical trials can begin. As a primary part of this process, metabolites must be identified and critically assessed to understand how the drug compound will affect human metabolism. Traditionally, this task has been costly and time consuming for drug makers, and commonly deferred until the final stages of preclinical testing.

This comarketing program provides customers with a turnkey solution that bridges the gap between sophisticated laboratory software and hardware capabilities. The analytical benefits of Agilent's high-resolution instruments, integrated with Molecular Discovery's robust predictive metabolite-identification software tools, will advance drug research and discovery by enabling the decisive identification and conversion of large volumes of data into usable information.


About Molecular Discovery Ltd.

Molecular Discovery Ltd. (www.moldiscovery.com) has been providing unique drug-discovery software solutions to the pharmaceutical industry since 1984, and active in the area of predictive metabolism since 2000. Molecular Discovery has led the way with its MetaSite, Mass-MetaSite and WebMetabase technologies as well as leading the first human Cytochrome P450 Consortium together with a number of pharmaceutical companies.


About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,000 employees serve customers in more than 100 countries. Agilent had net revenues of $6.6 billion in fiscal 2011. Information about Agilent is available at www.agilent.com.

# # #

Contact:

Susan Berg
+1 408 553 7093
susan_berg1@agilent.com

   
Record changed: 2016-03-19

Advertisement

Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px

More documents for Agilent (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 120x180px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px